• BioXcel Therapeutics entered a 10th amendment to its Oaktree-led credit agreement, setting a July 31, 2026 deadline for definitive deals.
• Required transactions must either repay all credit agreement obligations or deliver an alternative capital solution acceptable to lenders.
• Accrued interest through June 30, 2026 shifted to payment-in-kind, capitalized into loan principal.
• June 30 principal payment deferred to July 31, 2026; required payment set at $9.02 million, excluding additional accrued interest and fees through July 31.
• Minimum liquidity covenant cut to $7.5 million; board strategic process committee formed with exclusive authority over any restructuring or insolvency filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080501), on July 06, 2026, and is solely responsible for the information contained therein.